NEW YORK, June 5, 2026, 14:02 EDT
Dyadic International Inc. traded close to 72 cents on Friday on Nasdaq, almost flat for the day. The shares are still below an important listing level with under two weeks until shareholders vote on a reverse stock split. The company had a market cap of about $26.2 million, and trading volume was light.
Why does the stock matter? Dyadic is seeking shareholder approval for a reverse stock split, asking holders to vote on a ratio between 2-for-1 and 10-for-1 at its June 18 annual meeting. The proposal would combine existing shares and could push up the per-share price without changing Dyadic’s underlying value.
Pressure is on Dyadic. The company has told investors its stock needs to close at $1 or higher for at least 10 consecutive business days by June 17, or it risks falling out of compliance with Nasdaq’s minimum closing price rule.
Small growth stocks stayed under pressure as Wall Street dropped. U.S. payrolls climbed 172,000 in May, almost double the 85,000 forecast, fueling concerns about a longer stretch of tight Fed policy. “People are pricing in 100% probability of a Fed hike later this year,” said Charlie Ripley, senior investment strategist at Allianz Investment Management. Reuters
Biotech and platform stocks traded lower. The SPDR S&P Biotech ETF lost about 3%. Codexis slipped 7.5% and Ginkgo Bioworks gave up 9.7%. Dyadic’s smaller move fit a wider risk-off session, with no big company-specific move or catalyst in play.
Dyadic posted higher revenue for the first quarter at $1.1 million, up from $393,572 last year. Net loss came in at $2.0 million, or 5 cents per share, compared with a net loss of $2.0 million, or 7 cents per share, a year ago. The company had roughly $6.6 million in cash, restricted cash and investment-grade securities at the end of the quarter.
Dyadic is looking to make commercial products from its microbial production platforms. The company has called out orders for recombinant proteins in cultivated meat, albumin and enzyme markets. Recombinant proteins are made using engineered microbes or cells. President and COO Joe Hazelton said Dyadic is still focused on “transforming Dyadic into a commercially driven organization.” Dyadic
Dyadic and Scripps Research are working together on antibody and vaccine candidates for hantaviruses like Andes virus, according to the latest scientific update. Scripps professor Jiang Zhu said “manufacturing flexibility, scale and speed” have become more important after recent outbreaks. Dyadic CEO Mark Emalfarb said the COVID-19 pandemic exposed slow deployment and scaling as problems. Dyadic
Dyadic disclosed it needs funding. In March, the company got a Nasdaq deficiency notice for not meeting stockholders’ equity rules. Dyadic said the notice doesn’t affect its listing right now. Its quarterly report showed negative stockholders’ equity of $407,732 as of March 31.
The risks are clear. A reverse split might not hold shares above $1, and delisting could weigh on liquidity. Any equity raise would dilute existing holders if it happens, since each share could mean less ownership. Dyadic has an at-the-market share sale program that could bring in up to $4.238 million. The company said it might try to raise more money for product development, commercialization, working capital, or to keep its Nasdaq listing.
Next up are two key dates: the bid-price deadline on June 17 and the annual meeting on June 18. What comes after is less clear. Investors want to see if early commercial orders turn into repeat revenue, instead of just serving as technical proof.
